Literature DB >> 24453773

The incidence and prevalence of neuromyelitis optica: a systematic review.

Ruth Ann Marrie1, Caroline Gryba1.   

Abstract

Interest in neuromyelitis optica (NMO) has increased substantially over the last few years, but it is not known whether NMO has the same geographic and temporal variations in disease risk as multiple sclerosis (MS). We aimed to evaluate the worldwide incidence and prevalence of NMO through a systematic review of published peer-reviewed studies. We performed a search of the English-language literature using MEDLINE and EMBASE from January 1985 to March 2012. Search terms included "neuromyelitis optica," "Devic's," "opticospinal," "incidence," "prevalence," and "epidemiology." We assessed study quality using a standardized instrument. A total of five studies met the inclusion criteria. Three of the studies were from North America, and all studies were published between 2005 and 2012. All studies were of good quality, but only one study reported standardized rates, and subgroup-specific estimates were rarely reported. The incidence of NMO per 100,000 population ranged from 0.053 to 0.40, while the prevalence per 100,000 population ranged from 0.52 to 4.4. Heterogeneity was high among the incidence (I(2) = 68.0%) and prevalence studies (I(2) = 94.0%). This review highlights the limited knowledge regarding the epidemiology of NMO and the importance of obtaining estimates standardized to common populations to enhance comparability of studies from different jurisdictions. Future studies would also benefit from reporting age-, sex-, and race- or ethnicity-specific estimates.

Entities:  

Year:  2013        PMID: 24453773      PMCID: PMC3883026          DOI: 10.7224/1537-2073.2012-048

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  34 in total

1.  MS and neuromyelitis optica in Martinique (French West Indies).

Authors:  P Cabre; O Heinzlef; H Merle; G G Buisson; O Bera; R Bellance; J C Vernant; D Smadja
Journal:  Neurology       Date:  2001-02-27       Impact factor: 9.910

2.  Prevalence of multiple sclerosis in Canada: a systematic review.

Authors:  Alexandre Y Poppe; Christina Wolfson; Bin Zhu
Journal:  Can J Neurol Sci       Date:  2008-11       Impact factor: 2.104

3.  Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis.

Authors:  B A C Cree; O Khan; D Bourdette; D S Goodin; J A Cohen; R A Marrie; D Glidden; B Weinstock-Guttman; D Reich; N Patterson; J L Haines; M Pericak-Vance; C DeLoa; J R Oksenberg; S L Hauser
Journal:  Neurology       Date:  2004-12-14       Impact factor: 9.910

4.  Neuromyelitis optica in France: a multicenter study of 125 patients.

Authors:  N Collongues; R Marignier; H Zéphir; C Papeix; F Blanc; C Ritleng; M Tchikviladzé; O Outteryck; S Vukusic; M Fleury; B Fontaine; D Brassat; M Clanet; M Milh; J Pelletier; B Audoin; A Ruet; C Lebrun-Frenay; E Thouvenot; W Camu; M Debouverie; A Créange; T Moreau; P Labauge; G Castelnovo; G Edan; E Le Page; G Defer; B Barroso; O Heinzlef; O Gout; D Rodriguez; S Wiertlewski; D Laplaud; F Borgel; P Tourniaire; J Grimaud; B Brochet; P Vermersch; C Confavreux; J de Seze
Journal:  Neurology       Date:  2010-03-02       Impact factor: 9.910

5.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

6.  Brain abnormalities in neuromyelitis optica.

Authors:  Sean J Pittock; Vanda A Lennon; Karl Krecke; Dean M Wingerchuk; Claudia F Lucchinetti; Brian G Weinshenker
Journal:  Arch Neurol       Date:  2006-03

7.  Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica.

Authors:  Angelo Ghezzi; Roberto Bergamaschi; Vittorio Martinelli; Maria Trojano; M Rosaria Tola; Elisa Merelli; Luigi Mancardi; Paolo Gallo; Massimo Filippi; Mauro Zaffaroni; Giancarlo Comi
Journal:  J Neurol       Date:  2004-01       Impact factor: 4.849

8.  Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution.

Authors:  Elisa Bizzoco; Francesco Lolli; Anna Maria Repice; Bahia Hakiki; Mario Falcini; Alessandro Barilaro; Rosanna Taiuti; Gianfranco Siracusa; Maria Pia Amato; Tiziana Biagioli; Silvia Lori; Marco Moretti; Annalisa Vinattieri; Patrizia Nencini; Luca Massacesi; Sabrina Matà
Journal:  J Neurol       Date:  2009-05-28       Impact factor: 4.849

9.  Neuromyelitis optica: effect of gender.

Authors:  Dean M Wingerchuk
Journal:  J Neurol Sci       Date:  2009-09-08       Impact factor: 3.181

10.  Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis.

Authors:  Jeruza L Neyeloff; Sandra C Fuchs; Leila B Moreira
Journal:  BMC Res Notes       Date:  2012-01-20
View more
  16 in total

1.  Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase.

Authors:  P O Barros; T Cassano; J Hygino; T B Ferreira; N Centurião; T M Kasahara; R M Andrade; U C Linhares; A F B Andrade; C C F Vasconcelos; R Alvarenga; R Marignier; C A M Bento
Journal:  Clin Exp Immunol       Date:  2015-12-01       Impact factor: 4.330

Review 2.  Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder.

Authors:  Maureen A Mealy; Sharon L Kozachik; Michael Levy
Journal:  Pain Manag Nurs       Date:  2019-05-15       Impact factor: 1.929

3.  Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders.

Authors:  Cristina Valencia-Sanchez; Dean M Wingerchuk
Journal:  BioDrugs       Date:  2020-12-10       Impact factor: 5.807

Review 4.  Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later.

Authors:  Sean J Pittock; Claudia F Lucchinetti
Journal:  Ann N Y Acad Sci       Date:  2015-06-10       Impact factor: 5.691

5.  Neuromyelitis optica in pregnancy complicated by posterior reversible encephalopathy syndrome, eclampsia and fetal death.

Authors:  Catherine Igel; Diana Garretto; Matthew S Robbins; Michael Swerdlow; Nancy Judge; Ashlesha Dayal
Journal:  J Clin Med Res       Date:  2014-12-29

6.  Low levels of vitamin D in neuromyelitis optica spectrum disorder: association with disease disability.

Authors:  Ju-Hong Min; Patrick Waters; Angela Vincent; Hye-Jin Cho; Byung-Euk Joo; Sook-Young Woo; Soo-Youn Lee; Hee-Young Shin; Kwang Ho Lee; Byoung Joon Kim
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240

Review 7.  The Neuroepithelium Disruption Could Generate Autoantibodies against AQP4 and Cause Neuromyelitis Optica and Hydrocephalus.

Authors:  Leandro Castañeyra-Ruiz; Ibrahim González-Marrero; Agustín Castañeyra-Ruiz; Juan M González-Toledo; María Castañeyra-Ruiz; Francisco J Perez-Molto; Emilia M Carmona-Calero; Agustín Castañeyra-Perdomo
Journal:  Int Sch Res Notices       Date:  2014-10-29

8.  Placebo-controlled study in neuromyelitis optica-Ethical and design considerations.

Authors:  Bruce Ac Cree; Jeffrey L Bennett; Mark Sheehan; Jeffrey Cohen; Hans-Peter Hartung; Orhan Aktas; Ho Jin Kim; Friedemann Paul; Sean Pittock; Brian Weinshenker; Dean Wingerchuk; Kazuo Fujihara; Gary Cutter; Kaushik Patra; Armando Flor; Gerard Barron; Soraya Madani; John N Ratchford; Eliezer Katz
Journal:  Mult Scler       Date:  2015-12-14       Impact factor: 6.312

9.  Development of a patient-centred conceptual framework of health-related quality of life in neuromyelitis optica: a qualitative study.

Authors:  Abigail M Methley; Kerry Mutch; Perry Moore; Anu Jacob
Journal:  Health Expect       Date:  2015-11-24       Impact factor: 3.377

Review 10.  Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials.

Authors:  Georgina Flórez-Grau; Irati Zubizarreta; Raquel Cabezón; Pablo Villoslada; Daniel Benitez-Ribas
Journal:  Front Immunol       Date:  2018-05-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.